After pushing shares of Isis Pharmaceuticals Inc. to a 52-week high in late June on the first Phase II data of antisense drug Isis-ApoCIIIRx, investors were more cautious Monday when the company reported additional Phase II data on patients with high to severely high triglycerides on stable doses of fibrates.